A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne

Gómez, Sara; Gamazo, Carlos; Román, Beatriz San; Grau, Alicia; Espuelas, Socorro; Ferrer, Marta; Sánz, M L; Irache, Juan M.

doi:10.1016/j.jim.2009.06.005

Cited by 37 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In summary, the use of nanotechnology platforms, although widespread in recent years for vaccination purposes [98,106], is emerging in the field of allergen immunotherapy [103][104][105]. Given the promising results obtained so far, polymeric nanoparticles can be of interest to develop new therapeutic strategies able to improve both clinical efficacy and safety of allergen vaccines.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Cabrera

López

Gómez

et al. 2011

Drug and Chemical Toxicology

View full text Add to dashboard Cite

In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Moreover, these carriers were able to protect a model of sensitized mice to ovalbumin from anaphylactic shock. Thus, these PVMA nanoparticles have been widely used as carriers for controlled delivery of antigens such as Lolium perenne (allergenic proteins of rye-grass pollen) (N), [88,[103][104][105][106].…”

Section: Poly(anhydrides)mentioning

confidence: 99%

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Cabrera

López

Gómez

et al. 2011

Drug and Chemical Toxicology

View full text Add to dashboard Cite

show abstract

“…*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. demonstrated that these poly(anhydride) NPs are able to successfully encapsulate allergens (10,15,16). Thus, these NPs containing a protein extract from Lolium perenne induced a significant T H 1 response which protected the sensitized mice against severe anaphylactic symptoms induced by challenge (17). Furthermore, the encapsulation of peanut proteins into poly(anhydride) NPs enhanced their immunogenic properties by intradermal immunization in mice (12).…”

Section: Figmentioning

confidence: 97%

“…Poly(anhydride) nanoparticles have been successfully associated with several proteins, including allergens (15)(16)(17) and bacterial antigens (18,19), increasing their ability to induce protective immune responses after mucosal immunization. Likewise, previous studies had described the bioadhesive properties of poly(anhydride) nanoparticles (20).…”

mentioning

confidence: 99%

Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles

Rebouças

Irache

Camacho

et al. 2014

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…This observation demonstrated that the combination of the copolymer with LPS can induce a Th1 polarization that can counteract the existing Th2 polarization. 70 Parietaria pollen is characterized by the presence of two major allergens which are capable of inducing IgE production in the majority of allergic patients. For this reason, recombinant Parietaria major allergens were entrapped within two independent classes of NPs whose bioavailability was evaluated by means of a basophil activation assay, showing that complex formation does not inhibit their availability to the IgE antibodies of allergic patients.…”

mentioning

confidence: 99%

Nanoparticle–allergen complexes for allergen immunotherapy

Felice¹,

Colombo²

2017

IJN

View full text Add to dashboard Cite

Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

show abstract

A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne

Cited by 37 publications

References 35 publications

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles

Nanoparticle–allergen complexes for allergen immunotherapy

Contact Info

Product

Resources

About

A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne

Cited by 37 publications

References 35 publications

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles

Nanoparticle&ndash;allergen complexes for allergen immunotherapy

Contact Info

Product

Resources

About

Nanoparticle–allergen complexes for allergen immunotherapy